iBio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11750 Sorrento Valley Rd Ste 200, San Di...Phone Number
(979) 446-0027Website
www.ibioinc.comRevenue
<$5 MillionStock Symbol
IBIOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About iBio
iBio develops next-generation cardiometabolic and obesity therapeutics designed to promote higher-quality weight loss by preserving and building muscle, improving metabolic function, and supporting long-term treatment through more convenient dosing and enhanced tolerability, while complementing existing therapies. The company also advances a preclinical immuno-oncology pipeline targeting hard-to-treat solid tumors, including those in the breast, lung, and colorectal regions, as well as pancreatic cancer and glioblastoma. Its work is powered by a machine-learningdriven antibody discovery platform that provides core services such as precision epitope engineering, access to a proprietary fully human antibody library, antibody optimization through its StableHu technology, next-generation bispecific design via its EngageTx T-cell engager panel, and enhanced safety and developability through its ShieldTx masking system. The company is led by Martin Brenner, DVM, Ph.D., Chief Executive OfficeRead more
iBio Org Chart
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is iBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once iBio has new funding data
Click to see if iBio had a recent Job posting/layoffs
Product Launch: Get notified when iBio launches new products
Check if iBio has recently received funding, and reach out quickly before it becomes old news!
iBio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on iBio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at iBio
Check out if iBio is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined iBio as Masked Content
Find more new buyers
Compare Similar Companies to iBio
Compare insights from companies similar to iBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$95.1M
201-500
Private
-
2013
KM
Klaus MartinSenior Vice President and CEO, Biopharmaceuticals Business Unit
Company Profile Activity
Activity Insights
iBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
iBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about iBio.
iBio financials insights
Gather financial insights about iBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2025
Other Financing Round
$6.2M
iBio Tech Stack
A closer look at the technologies used by iBio
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
New Hire
Executive Move
Executive Moves, New Hire
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Legal Affairs, Stake & Stock Ownership, Finance
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
iBio News & Media
IBIO 10-Q Filings - Ibio SEC 10-Q - Stock Titan
Every Ibio (IBIO) 10-Q filed with the SEC in the last 24 months, newest first, each with a summary and the impact and sentiment scores our analysis gives it.iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston.iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress.Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares
Lynx1 Capital Management and Weston Nichols report 5.4% beneficial ownership in iBio, including 2,807,016 shares issuable from Series F warrants subject to a 9.99% blocker.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding iBio
Sign Up For FreeTo access detailed company insights
iBio develops next-generation cardiometabolic and obesity therapeutics designed to promote higher-quality weight loss by preserving and building muscle, improving metabolic function, and supporting long-term treatment through more convenient dosing and enhanced tolerability, while complementing existing therapies. The company also advances a precli... Read More
